These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 31358010)

  • 1. Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy.
    Xu L; Cheng Z; Cui C; Wu X; Yu H; Guo J; Kong Y
    J Transl Med; 2019 Jul; 17(1):245. PubMed ID: 31358010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy.
    Kong Y; Sheng X; Wu X; Yan J; Ma M; Yu J; Si L; Chi Z; Cui C; Dai J; Li Y; Yu H; Xu T; Tang H; Tang B; Mao L; Lian B; Wang X; Yan X; Li S; Guo J
    Clin Cancer Res; 2017 Nov; 23(22):6946-6957. PubMed ID: 28830923
    [No Abstract]   [Full Text] [Related]  

  • 3. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.
    Cen L; Carlson BL; Schroeder MA; Ostrem JL; Kitange GJ; Mladek AC; Fink SR; Decker PA; Wu W; Kim JS; Waldman T; Jenkins RB; Sarkaria JN
    Neuro Oncol; 2012 Jul; 14(7):870-81. PubMed ID: 22711607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma.
    Yu J; Yan J; Guo Q; Chi Z; Tang B; Zheng B; Yu J; Yin T; Cheng Z; Wu X; Yu H; Dai J; Sheng X; Si L; Cui C; Bai X; Mao L; Lian B; Wang X; Yan X; Li S; Zhou L; Flaherty KT; Guo J; Kong Y
    Clin Cancer Res; 2019 Nov; 25(21):6511-6523. PubMed ID: 31375512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.
    Young RJ; Waldeck K; Martin C; Foo JH; Cameron DP; Kirby L; Do H; Mitchell C; Cullinane C; Liu W; Fox SB; Dutton-Regester K; Hayward NK; Jene N; Dobrovic A; Pearson RB; Christensen JG; Randolph S; McArthur GA; Sheppard KE
    Pigment Cell Melanoma Res; 2014 Jul; 27(4):590-600. PubMed ID: 24495407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor, in patients with advanced head and neck mucosal melanoma harboring CDK4 amplification.
    Shi C; Ju H; Zhou R; Xu S; Wu Y; Gu Z; Wang Y; Chen W; Huang X; Han Y; Sun S; Li C; Wang M; Zhou G; Zhang Z; Li J; Ren G
    BMC Med; 2024 May; 22(1):215. PubMed ID: 38807144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detecting copy number alterations of oncogenes in cell-free DNA to monitor treatment response in acral and mucosal melanoma.
    Mikoshiba A; Ashida A; Sakaizawa K; Kiniwa Y; Okuyama R
    J Dermatol Sci; 2020 Mar; 97(3):172-178. PubMed ID: 31987696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma.
    Hsu CL; Lui KW; Chi LM; Kuo YC; Chao YK; Yeh CN; Lee LY; Huang Y; Lin TL; Huang MY; Lai YR; Yeh YM; Fan HC; Lin AC; Lu YJ; Hsieh CH; Chang KP; Tsang NM; Wang HM; Chang AY; Chang YS; Li HP
    J Exp Clin Cancer Res; 2018 Sep; 37(1):233. PubMed ID: 30236142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the cell-cycle regulatory proteins (pRb, cyclin D1, p16INK4A and cdk4) in human endometrial cancer: correlation with clinicopathological features.
    Semczuk A; Miturski R; Skomra D; Jakowicki JA
    Arch Gynecol Obstet; 2004 Jan; 269(2):104-10. PubMed ID: 14648178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of cyclin D1, CDK4 and p27KIP1 is associated with the p16MTS1 gene status in human esophageal carcinoma cell lines.
    Kitahara K; Yasui W; Yokozaki H; Semba S; Hamamoto T; Hisatsugu T; Tahara E
    J Exp Ther Oncol; 1996 Jan; 1(1):7-12. PubMed ID: 9414383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors.
    Namazie A; Alavi S; Olopade OI; Pauletti G; Aghamohammadi N; Aghamohammadi M; Gornbein JA; Calcaterra TC; Slamon DJ; Wang MB; Srivatsan ES
    Laryngoscope; 2002 Mar; 112(3):472-81. PubMed ID: 12148857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
    Bartkova J; Lukas J; Guldberg P; Alsner J; Kirkin AF; Zeuthen J; Bartek J
    Cancer Res; 1996 Dec; 56(23):5475-83. PubMed ID: 8968104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway.
    Mao L; Dai J; Cao Y; Bai X; Sheng X; Chi Z; Cui C; Kong Y; Zhang Y; Wu L; Wang X; Tang B; Lian B; Yan X; Li S; Zhou L; Wei X; Li C; Qi Z; Si L; Guo J
    Eur J Cancer; 2021 May; 148():297-306. PubMed ID: 33770575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palbociclib for treatment of metastatic melanoma with copy number variations of CDK4 pathway: case report.
    Tang B; Sheng X; Kong Y; Chi Z; Si L; Cui C; Yan X; Mao L; Lian B; Li S; Wang X; Dai J; Bai X; Zhou L; Guo J
    Chin Clin Oncol; 2018 Dec; 7(6):62. PubMed ID: 30180747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early G₁ cyclin-dependent kinases as prognostic markers and potential therapeutic targets in esophageal adenocarcinoma.
    Ismail A; Bandla S; Reveiller M; Toia L; Zhou Z; Gooding WE; Kalatskaya I; Stein L; D'Souza M; Litle VR; Peters JH; Pennathur A; Luketich JD; Godfrey TE
    Clin Cancer Res; 2011 Jul; 17(13):4513-22. PubMed ID: 21593195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6.
    Tang LH; Contractor T; Clausen R; Klimstra DS; Du YC; Allen PJ; Brennan MF; Levine AJ; Harris CR
    Clin Cancer Res; 2012 Sep; 18(17):4612-20. PubMed ID: 22761470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma.
    Edmunds SC; Kelsell DP; Hungerford JL; Cree IA
    Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):2845-51. PubMed ID: 12202501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib.
    Li P; Zhang X; Gu L; Zhou J; Deng D
    PLoS One; 2019; 14(10):e0223084. PubMed ID: 31652270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeras of p14ARF and p16: functional hybrids with the ability to arrest growth.
    Williams RT; Barnhill LM; Kuo HH; Lin WD; Batova A; Yu AL; Diccianni MB
    PLoS One; 2014; 9(2):e88219. PubMed ID: 24505435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
    Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
    Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.